Table 2.
Pooled incidence of treatment-related adverse events.
| Adverse events | Treatment | All grades | Grades 3 | |||||
|---|---|---|---|---|---|---|---|---|
| Included study (n) | Pooled rate [95%CI] | P value | Included study (n) | Pooled rate [95%CI] | P value | |||
| Anemia | Combination therapy | 9 | 55% [39%, 70%] | 0.001 | 9 | 22% [9%, 36%] | 0.03 | |
| Monotherapy | 8 | 24% [13%, 34%] | 8 | 6% [3%, 9%] | ||||
| Overall | 17 | 40% [24%, 57%] | 17 | 15% [9%, 21%] | ||||
| Thrombocytopenia | Combination therapy | 8 | 62% [45%, 80%] | 0.43 | 8 | 43% [24%, 62%] | 0.05 | |
| Monotherapy | 8 | 46% [9%, 83%] | 8 | 21% [10%, 32%] | ||||
| Overall | 16 | 54% [32%, 77%] | 16 | 32% [21%, 43%] | ||||
| Neutropenia | Combination therapy | 8 | 59% [42%, 77%] | 0.12 | 9 | 54% [40%, 68%] | 0.001 | |
| Monotherapy | 6 | 37% [15%, 59%] | 6 | 23% [11%, 35%] | ||||
| Overall | 14 | 50% [32%, 67%] | 15 | 41% [27%, 56%] | ||||
| Leukopenia | Combination therapy | 4 | 57% [21%, 92%] | 0.43 | 4 | 49% [18%, 81%] | 0.07 | |
| Monotherapy | 6 | 39% [15%, 63%] | 6 | 19% [9%, 29%] | ||||
| Overall | 10 | 46% [24%, 69%] | 10 | 32% [15%, 48%] | ||||
| Lymphopenia | Combination therapy | 3 | 25% [14%, 36%] | 0.42 | 3 | 21% [6%, 36%] | 0.38 | |
| Monotherapy | 3 | 45% [-1%, 91%] | 3 | 38% [3%, 72%] | ||||
| Overall | 6 | 36% [13%, 60%] | 6 | 30% [13%, 46%] | ||||
| Fatigue | Combination therapy | 6 | 38% [20%, 56%] | 0.11 | 4 | 1% [0%, 3%] | 0.02 | |
| Monotherapy | 7 | 22% [12%, 31%] | 2 | 10% [3%, 17%] | ||||
| Overall | 13 | 29% [20%, 37%] | 6 | 2% [0%, 3%] | ||||
| Fever/Pyrexia | Combination therapy | 7 | 24% [16%, 32%] | 0.66 | 3 | 7% [4%, 11%] | 0.19 | |
| Monotherapy | 8 | 22% [11%, 32%] | 2 | 4% [1%, 7%] | ||||
| Overall | 15 | 23% [15%, 30%] | 5 | 5% [3%, 8%] | ||||
| Nausea | Combination therapy | 4 | 78% [70%, 85%] | 0.0003 | 3 | 11% [5%, 18%] | 0.006 | |
| Monotherapy | 8 | 41% [24%, 59%] | 2 | 2% [0%, 4%] | ||||
| Overall | 12 | 53% [36%, 70%] | 5 | 5% [1%, 9%] | ||||
| Vomiting | Combination therapy | 7 | 41% [19%, 64%] | 0.18 | 5 | 7% [4%, 9%] | 0.004 | |
| Monotherapy | 6 | 23% [10%, 37%] | 3 | 2% [0%, 4%] | ||||
| Overall | 13 | 33% [21%, 44%] | 8 | 3% [2%, 5%] | ||||
| Diarrhea | Combination therapy | 5 | 31% [10%, 53%] | 0.48 | 2 | 2% [-1%, 5%] | 0.84 | |
| Monotherapy | 8 | 23% [15%, 31%] | 3 | 2% [0%, 3%] | ||||
| Overall | 13 | 26% [17%, 34%] | 5 | 2% [0%, 3%] | ||||
| Constipation | Combination therapy | 5 | 21% [6%, 35%] | 0.87 | 2 | 2% [-1%, 4%] | — | |
| Monotherapy | 5 | 19% [10%, 28%] | 0 | — | ||||
| Overall | 10 | 20% [11%, 28%] | 2 | 2% [-1%, 4%] | ||||
| Decrease appetite | Combination therapy | 5 | 26% [19%, 34%] | 0.57 | 3 | 6% [3%, 8%] | 0.29 | |
| Monotherapy | 5 | 32% [13%, 51%] | 4 | 4% [1%, 6%] | ||||
| Overall | 10 | 29% [20%, 38%] | 7 | 5% [3%, 6%] | ||||
| Hypokalemia | Combination therapy | 4 | 26% [14%, 38%] | 0.004 | 3 | 8% [3%, 13%] | 0.03 | |
| Monotherapy | 3 | 7% [3%, 11%] | 1 | 2% [-1%, 4%] | ||||
| Overall | 7 | 18% [10%, 27%] | 4 | 6% [1%, 10%] | ||||
The bold values indicated for significant differences (P<0.05).